NewEdge Advisors’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.66M Buy
1,546,883
+315,150
+26% +$1.98M 0.03% 552
2026
Q2
$7M Buy
1,231,733
+200,621
+19% +$981K 0.02% 634
2026
Q1
$4.42M Buy
1,031,112
+78,946
+8% +$440K 0.02% 747
2025
Q4
$8.53M Buy
+952,166
New +$5.9M 0.03% 486

Other funds holding NUVB

NewEdge Advisors's NUVB Position: Q3 2026 in Review

NewEdge Advisors increased its Nuvation Bio (NUVB) stake by 26% in Q3 2026, buying an estimated $1.98M and bringing the position to 1,546,883 shares worth $8.66M. The position accounts for 0.03% of the portfolio, ranked #552.

NewEdge Advisors first reported a position in NUVB in Q4 2025 and has held it in 4 quarters since. 258 funds tracked by Wall St. Rank hold NUVB as of Q3 2026.

  • NewEdge Advisors held 1,546,883 shares of Nuvation Bio worth $8.66M as of Q3 2026.
  • NewEdge Advisors bought 315,150 Nuvation Bio shares in Q3 2026, an estimated $1.98M.
  • Nuvation Bio made up 0.03% of NewEdge Advisors's portfolio in Q3 2026, its #552 holding.
  • NewEdge Advisors first reported a position in Nuvation Bio in Q4 2025 and has held it in 4 quarters since.
  • 258 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2026.

Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.